Two New Biotech IPOs Debut Friday, One Deal Delayed

Although

and

are the most hyped deals of the week, there are two other biotech deals that will debut on Friday, January 30.

is a biotech company focused on developing therapies for cancer, macular degeneration, and fibrotic diseases. The company's lead product candidate is TRC105, which is being tested in multiple different solid tumors. Some of the trials using TRC105 are sponsored by the National Cancer Institute. On January 9, the company announced results from a Phase 1/2 study of TRC105 in Combination with Sorafenib in Hepatocellular Carcinoma (HCC). The results were presented at the American Society of Clinical Oncology (ASCO) 2015 Gastrointestinal Cancers Symposium held from January 15-17. The company is offering 3.6 million shares and the underwriters are Wells Fargo, Stifel, Needham and Oppenheimer. The price range is $12 - $15 and the deal is expected to price Thursday night and trade Friday.

is a medical device company that sells image-guided catheter systems. The products help physicians treat patients with peripheral arterial disease. Avinger has revenues of about $11.5 million and lost about $32.4 million over the last 12 months. The company is offering 4.62 million shares and the underwriters are Canaccord Genuity, Cowen, Oppenheimer, BTIG, and Stephens. The price range is $12 - $14 and the deal is expected to price Thursday night and trade Friday.

also markets optical catheters and was originally supposed to debut on Friday. The deal has been pushed out to next week due to weather.